J. Oddo

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.

M. Vitek, Joseph O. Moore, J. Gockerman, 2011, Blood.

Apolipoprotein E and Peptide Mimetics Modulate Inflammation by Binding the SET Protein and Activating Protein Phosphatase 2A

C. Colton, M. Vitek, J. Neil, 2011, The Journal of Immunology.

Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

R. Sears, M. Odero, B. Druker, 2014, Clinical Cancer Research.

Effects of flavor conditioning on postweaning performance of piglets fed a diet containing spray-dried porcine plasma

M. Gracia, J. Mallo, J. Oddo, 2016 .

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer

Colin J. Daniel, Ellen M. Langer, R. Sears, 2014, Proceedings of the National Academy of Sciences.

Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer

Colin J. Daniel, R. Sears, M. Vitek, 2014, Molecular Cancer Research.

A Novel SET Antagonist (OP449) Is Cytotoxic to CML Cells, Including the Highly-Resistant BCR-ABLT315I Mutant, and Demonstrates Enhanced Efficacy in Combination with ABL Tyrosine Kinase Inhibitors,

B. Druker, M. Vitek, A. Agarwal, 2011 .